System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Francesco Bertoni, MD is an expert in Hematology at Ente Ospedaliero Cantonale (Switzerland). As of October 2026, ScienceLeadR ranks Francesco Bertoni in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Francesco Bertoni has authored 917 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 1 of them ongoing. SLR score: 2,921 (community average: 125). How the SLR is computed.

LeadR Profile

Francesco Bertoni, MD Ente Ospedaliero Cantonale Switzerland
2 921 ScienceLeadR Reputation 2921

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1995 - 2026
Source: PubMed

Institute of Oncology Research

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 917

Citations

Citations: 34 197 1st author: 90 Last author: 325 Unique author: 10

Main journals

Blood 107
Cancer Res 60
Br J Haematol 51
Hematol Oncol 51
Haematologica 26

Best Journals

N Engl J Med 5
Ann Oncol 2
Nature 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
BTK/BCL2 dual targeting enhances apoptosis in marginal zone lymphoma: preclinical activity of tacabrutideg (BGB-16673) and sonrotoclax.
PMID 42817838 — cells, growth, hematology, lymphoma, rituximab, cell line, lenalidomide, apoptosis		Haematologica20260
Surface expression of ROR1 across lymphoma cell lines identifies models for preclinical evaluation of ROR1-targeting antibody-drug conjugates.
PMID 42704791 — cells, pharmaceutical preparations, lymphoma, leukemia, cell line, preclinical evaluation		Leuk Lymphoma20260
SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma.
PMID 42669887 — lymphoma, follicular, lymphoma, rituximab		Br J Haematol20260
BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?
PMID 42360198		Blood Cancer Discov20260
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 Trial.
PMID 42279347 — cells, safety, hodgkin disease, pharmaceutical preparations, lymphoma, neutropenia, drug-related side effects and adverse reactions, lymphoma, non-hodgkin, therapeutics, b-lymphocytes		Cancers (Basel)20260

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 1

By phase:

Phase 1 3
N/A 2
Phase 2 2
Phase 1/Phase 2 1
Phase 3 1

By status:

Completed 4
Active not recruiting 1
Not yet recruiting 1
Recruiting 1
Terminated 1
Unknown 1

By type:

Interventional 7
Observational 2

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 2
multicentric5to9 1
multicentricup10 3

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Molecular and Cellular Characterization of MALT Lymphoma
NCT07376330 — cells, lymphoma, b-cell, lymphoma, neoplasms, lymphoma, b-cell, marginal zone, b-lymphocytes, edible grain		N/ANot yet recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS